NOVO-B:CPH
Novo Nordisk A/S
259,60Â DKK
arrow_downward
-1,46%(-3,85) 1D
16 tet, 5:00:00 m.d., GMT+2 · DKK
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për NOVO-B...
Hap
261,00Â DKK
I lartë
262,15Â DKK
I ulët
259,35Â DKK
Kapitalizimi i tregut
893,13Â mld
Vëllimi mesatar
5,23Â mln
Vëllimi
5,27Â mln
Maksimumi 52-javor
409,95Â DKK
Minimumi 52-javor
224,25Â DKK
Aksionet në qarkullim
3,39Â mld
Numri i punonjësve
67 mijë
Hap
261,00Â DKK
I lartë
262,15Â DKK
I ulët
259,35Â DKK
Kapitalizimi i tregut
893,13Â mld
Vëllimi mesatar
5,23Â mln
Vëllimi
5,27Â mln
Maksimumi 52-javor
409,95Â DKK
Minimumi 52-javor
224,25Â DKK
Aksionet në qarkullim
3,39Â mld
Numri i punonjësve
67 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
The Motley Fool
·
9 orë më parë
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
ad-hoc-news.de
·
10 orë më parë
Novo-Nordisk stock: Citi cuts target for Novo-Nordisk stock to DKK 296
Traders Union
·
18 orë më parë
Novo Nordisk shares technical analysis: Buyer support underpins upward price move
Foreign Policy Journal
·
1 ditë më parë
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
Profili
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Rreth Novo Nordisk A/S
Drejtori ekzekutivMaziar Mike Doustdar
Punonjësit66,7 mijë
Themeluar më1923
SeliaBagsværd, Capital Region of Denmark, Danimarkë
Sektori-
Uebsajtinovonordisk.com